Pseudoprogression has been reported, especially after therapy with CTLA-4 inhibitors in patients with melanoma [7], and less frequently in other tumor types (possibly in less than 5% of patients with other diseases, including NSCLC and lymphoma) [43]. The gene discussed is CTLA4; the disease is melanoma.